Literature DB >> 16713537

An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo.

Catalin M Lupu1, Christoph Eisenbach, Michael A Kuefner, Jan Schmidt, Alaviana D Lupu, Wolfgang Stremmel, Jens Encke.   

Abstract

We established an orthotopic animal model of colon cancer in mice and applied this model to study the antitumor effects of B7-H3, the newest member of the B7 family of costimulatory molecules. Colon-26 murine colon adenocarcinoma cells were inoculated into the cecal subserosum of mice to induce colon tumor growth. The tumor growth rate and the survival time of the mice were observed. A stable B7-H3 transfected Colon-26 cell line was established and the immunogenic effect was investigated. All mice implanted with wild-type tumor cells had tumor growth in the colon and died. The mean survival rate was 23 days. Mice implanted with C26-B7-H3 had a significantly prolonged survival time of 38 days. Our data suggest that B7-H3 exerts an antitumor effect on adenocarcinoma of the colon and may be considered as an adjuvant immunotherapy in the treatment of colon cancers. Our orthotopic animal model of colon cancer in mice could be applied to in vivo experimental studies of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713537     DOI: 10.1007/bf03239969

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

1.  Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Authors:  Katsuji Nakamura; Hiroyuki Sugumi; Atsumi Yamaguchi; Toshimitsu Uenaka; Yoshihiko Kotake; Toshimi Okada; Junichi Kamata; Jun Niijima; Takeshi Nagasu; Nozomu Koyanagi; Hiroshi Yoshino; Kyosuke Kitoh; Kentaro Yoshimatsu
Journal:  Mol Cancer Ther       Date:  2002-01       Impact factor: 6.261

2.  An ultra-metastatic model of human colon cancer in nude mice.

Authors:  F X Sun; A R Sasson; P Jiang; Z An; R Gamagami; L Li; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.

Authors:  R N La Motte; A H Sharpe; J A Bluestone; M B Mokyr
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

4.  A new animal model for human colon cancer metastasis.

Authors:  R S Bresalier; S E Raper; E S Hujanen; Y S Kim
Journal:  Int J Cancer       Date:  1987-05-15       Impact factor: 7.396

5.  Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.

Authors:  K S Zier; B Gansbacher
Journal:  Eur J Cancer       Date:  1996-07       Impact factor: 9.162

6.  Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma.

Authors:  K B Pham-Nguyen; W Yang; R Saxena; S N Thung; S L Woo; S H Chen
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

7.  Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.

Authors:  Muthukumaran Sivanandham; Christos I Stavropoulos; Eugene M Kim; Brian Mancke; Marc K Wallack
Journal:  Cancer Immunol Immunother       Date:  2002-01-29       Impact factor: 6.968

8.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

9.  Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice.

Authors:  R Giavazzi; D E Campbell; J M Jessup; K Cleary; I J Fidler
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

View more
  25 in total

Review 1.  Biology and significance of circulating and disseminated tumour cells in colorectal cancer.

Authors:  Gunnar Steinert; Sebastian Schölch; Moritz Koch; Jürgen Weitz
Journal:  Langenbecks Arch Surg       Date:  2012-02-15       Impact factor: 3.445

2.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

Review 3.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

4.  The contrasting role of B7-H3.

Authors:  Kimberly A Hofmeyer; Anjana Ray; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

5.  Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Authors:  Hiroko Kobori; Masaaki Hashiguchi; Jinhua Piao; Moriyuki Kato; Patcharee Ritprajak; Miyuki Azuma
Journal:  Immunology       Date:  2010-02-05       Impact factor: 7.397

Review 6.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

Review 8.  Fine tuning the immune response through B7-H3 and B7-H4.

Authors:  Kyung H Yi; Lieping Chen
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.

Authors:  Masaaki Hashiguchi; Hiroko Kobori; Patcharee Ritprajak; Yosuke Kamimura; Haruo Kozono; Miyuki Azuma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

10.  Clinical importance of B7-H3 expression in human pancreatic cancer.

Authors:  I Yamato; M Sho; T Nomi; T Akahori; K Shimada; K Hotta; H Kanehiro; N Konishi; H Yagita; Y Nakajima
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.